OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers and vascular anomalies that are underserved by available therapies
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers and vascular anomalies that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a pipeline of small molecule drugs designed to achieve optimal efficacy and tolerability by selectively targeting specific mutations shown to be key drivers of cancer and other diseases.